Spotlight On... Novartis takes biosimilar fight to Supreme Court; Alphabet's Verily leases ex-Onyx campus; and more...

Novartis ($NVS) is petitioning the Supreme Court to weigh in on biosimilars legislation, challenging a ruling that forces the makers of copycat biologics to wait 180 days after approval before launching their products. At issue is a U.S. law that requires makers of biosimilars to warn brand-name manufacturers 180 days before selling their knockoffs, STAT reports. As the law is currently enforced, that process starts when biosimilars win approval, but Novartis contends it should be at the whim of developers, meaning companies could inform their rivals 180 days before the FDA's scheduled decision date and thus launch their copycat therapies immediately following approval. Novartis' Sandoz unit has filed a petition in hopes of making its case before the Supreme Court in what could lead to a landmark decision for biosimilars in the U.S. More

@FierceBiotech: Academic medical centers get an F for trial transparency. Article | Follow @FierceBiotech

@JohnCFierce: Third Rock launches Pliant, gambling $45M on a next-gen approach to fibrosis. Report | Follow @JohnCFierce

@DamianFierce: de Saussure Capital. More | Follow @DamianFierce

> Verily, formerly Google Life Sciences, has leased the 400,000-square-foot California campus that once housed Onyx Pharmaceuticals, grabbing a site with space for up to 1,000 workers, the San Francisco Business Times reports. News

> Cancer MoonShot 2020, a public-private research group led by Patrick Soon-Shiong's NantWorks, recruited 10 hospitals and research centers to join a pediatrics-focused consortium, teaming up for oncology R&D. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Virtual reality startup reels in $100M for rehabilitation device. Article | Follow @FierceMedDev

@VarunSaxena2: Direct Flow Medical throws its hat in the transcatheter mitral valve arena ring. Article | Follow @VarunSaxena2

@EmilyWFierce: In Dx Digest: Sysmex and Eisai focus on dementia tests and Apogenix gets €3 million for cancer companion Dx. Report | Follow @EmilyWFierce

> Novartis buys minimally invasive glaucoma surgery player to boost its Alcon eyecare unit. Story

> FDA downplayed fetal deaths linked to Bayer's Essure contraceptive: Analyst. Report

> IBM Watson Health to buy Truven for $2.6B in fourth health data deal. Article

Pharma News

@FiercePharma: India aims to detail new policies next month to boost bulk drug output. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: New York gives $200M for Athenix to build Buffalo plant. Company pledges 900 jobs over 10 years. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Merck's new hep C contender Zepatier faces a long runway, but 2017 could bring takeoff. Article | Follow @CarlyHFierce

> NEJM study finds Actos holds off repeat strokes, heart attacks in insulin-resistant patients. Article

> U.K. cost gatekeepers say 'show me' to Alexion's new rare disease med Kanuma. Report

> FDA underestimated fetal deaths linked to Bayer's Essure contraceptive: Analyst. More

CRO News

> Former GSK staffers help Parexel expand genomics offering. Story

> AMRI scores a revenue jump after a spate of deals. Article

> INC cozies up to trial sites in hopes of improving R&D results. Report

> CRO Analytics raises cash to advance its cloud-based data service. News

Pharma Manufacturing News

> Cipla secures first U.S. manufacturing plant. News

> AMRI's revenues soar 45% as refocus on contract manufacturing pays off. More

> GSK targets Indian plant for $73M in upgrades. Report

> Compounder recalls superpotent morphine tied to adverse reactions in babies. Story

> Biotech Alnylam commits $100M to plant for its RNAi therapy. Article

Pharma Asia News

> Athenex details $225M China-New York drug manufacturing play. Item

> S. Africa hauls up India's Ranbaxy over bacteria found in folic acid tablets. Story

> Lightstone Ventures joins with Singapore for $50M fund. News

> Sosei revs up work with Heptares candidates, seeks partners. Report

> India aims to detail new policies next month to boost bulk drug output. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.